Pharmaceutical co-crystal: An emerging approach to improve physical property

International Journal of Pharmaceutical Sciences Review and Research

Volumn 8, Issue 1, 2011, Pages 144-148

  Upadhyay, N ^a   Shukla, T P ^a   Mathur, A ^a   Manmohana, ^a   Jha, S K ^a  

^a NIMS UNIVERSITY   (India)

Author keywords

Co crystallization; Heterosynthon; Hydrogen bonding; Polymorphism; Supramolecular synthesis

Indexed keywords

CAFFEINE; CARBAMAZEPINE; ISONICOTINAMIDE; NANOCRYSTAL; NICOTINAMIDE; OXALIC ACID; PIROXICAM; SACCHARIN; SODIUM CHLORIDE; SUCCINIC ACID; THEOPHYLLINE; UREA;

CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; HYDROGEN BOND; NANOPHARMACEUTICS; REVIEW; SCREENING TEST; SOLVATE; STOICHIOMETRY; SUPRAMOLECULAR CHEMISTRY; THERMOSTABILITY;

EID: 79957657067     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Shan N, Zaworotko MJ. The role of co-crystals in pharmaceutical science.Drug Discovery Today 2008; 13:440-446.
2. Almarsson O, Zaworotko MJ: Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? ChemComm 1889-1896, 2004
3. Zaworotko M. Crystal engineering of co-crystals and their relevance to pharmaceuticals and solid-state chemistry. ActaCryst 2008; A64: C11-C12.
4. Trask AV. An overview of pharmaceutical co-crystals as intellectual property.MolPharma 2007; 4:301-309.
5. Jayasankar A, Somwangthanaroj A, Shao ZJ, Rodriguez- Hornedo N. Co-crystal formation during cogrinding and storage is mediated by amorphous phase. Pharm Res 2006; 23: 2381-2392.
6. Aakeroy CB, Salmon DJ. Building co-crystals with molecular sense and supramolecular sensibility.CrystEngComm 2005; 7:439-448.
7. Schultheiss N, Newman A. Pharmaceutical co-crystals and their physicochemical properties. Cryst Growth Des.2009; 9: 2950-2967.
8. Tiekink ERT, Vittal JJ (Editors). Frontiers in Crystal Engineering, John Wiley & Sons, Ltd, 2006, Chapter 2: Crystal Engineering of Pharmaceutical Co-crystals, pp 25-50.
9. Stahly GP. Diversity in single-and multiple-component crystals. The search for and prevalence of polymorphs and co-crystals. Cryst Growth Des 2007; 7:1007-1026.
10. McMahon JA. Crystal Engineering of Novel Pharmaceutical Forms.Master of Science Thesis, Department of Chemistry, University of South Florida, USA, 2006.
11. Shan N, Zaworotko MJ. The role of co-crystals in pharmaceutical science.Drug Discovery Today 2008; 13:440-446.
12. Jones W, Motherwell WDS, Trask AV. Pharmaceutical cocrystals: An Emerging approach to physical property enhancement. MRS Bull 2006; 31:875.
13. Rodríguez-Hornedo N, Nehm SJ, Jayasankar A, Co crystals: design, properties and formation mechanisms, In Encyclopedia of Pharmaceutical Technology, 3rd Ed, Taylor & Francis, London, 2007, 615-635.
14. Vishweshwar P, McMahon JA, Peterson ML, Hickey MB, Shattock TR, Zaworotko MJ. Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical-cal ingredients. Chem Commun.2005; 4601-4603.
15. Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, Cima MJ, Gardner CR. Highthroughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliver Rev 2004; 56:275-300.
16. Byrn SR, Pfeiffer RR, Stowell JG: Solid-State Chemistry of Drugs. 2nd edition. SSCI Inc, West Lafayette 1999.
17. Otto S, Sanders JM: Encyclopedia of supramolecular chemistry. Vol.2. CRC, Taylor Francis, 2004.
18. Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection, and use. New York: Wiley-VCH; 2002.p 374
19. Serajuddin ATM. Salt formation to improve drug solubility. Advanced Drug Delivery Rev 2007; 59: 603-616.
20. Whitesides GM, Wong AP. The intersection of biology and materials science.MRS Bull 2006; 31:19-27.
21. Porter WW, III, Elie SC, Matzger AJ.Polymorphism in carbamazepine co-crystals.Cryst Growth Des 2008; 8:14-16.
22. Ter Horst JH, Cains PW. Co-Crystal polymorphs from a solvent-mediated transformation Cryst Growth Des 2008; 8: 2537-2542.
23. Aitipamula S, Chow PS, Tan RBH. Dimorphs of a 1: 1 cocrystal of ethenzamide and saccharin: solid-state grinding methods result in metastable polymorph. CrystEngComm 2009; 11: 889-895.
24. Lu J, Rohani S. Preparation and characterization of theophylline-nicotinamide co-crystal. Org Process Res Dev, Article ASAP DOI: 10.1021/op900047r Publication Date (Web): May 28, 2009.
25. Shiraki K, Takata N, Takano R, Hayashi Y, Terada K. Dissolution improvement and the mechanism of the improvement from co-crystallization of poorly watersoluble compounds. Pharm Res 2008; 25:2581-2592.
26. Callear SK. Preparation, characterization and structural analysis of salts and co-crystals of organic compounds. University of Southampton, School of Chemistry, PhD Thesis, 2008, 253pp. http://eprints.soton.ac.uk/51224/]
27. Wenger M, Bernstein J. An alternate crystal form of gabapentin: A co crystal with oxalic acid. Cryst Growth Des 2008; 8: 1595-1598.
28. Fahlman, B. D. Materials Chemistry; Springer: Mount Pleasant, MI, 2007; Vol. 1, pp 282- 283.
29. Müller RH, Keck CM. Second generation of drug nanocrystals for delivery of poorly soluble drugs: smart Crystal technology. European Journal of Pharmaceutical Sciences 2008; 34:S20- S21; 19th Helsinki Drug Research 2008, June 9-11, 2008, Helsinki, Finland, Abstracts: 19th Helsinki Drug Research 2008.
30. Walsh RDB, Bradner MW, Fleischman S et al.: Crystal engineering of the composition of pharmaceutical phases. Chem-Comm. 186-187, 2003.
31. Karki S, Friscic T, Jones W. Control and interconversion of co-crystal stoichiometry in grinding: stepwise mechanism for the formation of a hydrogen-bonded co crystal. CrystEngComm 2009; 11: 470-481.
32. Ter Horst JH, Cains PW. Co-Crystal polymorphs from a solvent-mediated transformation Cryst Growth Des 2008; 8: 2537-2542.
33. Alexander R, Borden F, Spragg R, Using Raman Spectroscopy to Characterize Pharmaceutical Co-crystals. PerkinElmer LAS, NizarIssa, Robert Lancaster, University College, London.
34. Padrela L, Rodrigues MA, Velaga SP, Matos HA, Azevedo EG. Formation of indomethacin-saccharin co-crystals using supercritical fluid technology. Eur J Pharm Sci 2009; online 27 May 2009.